NASDAQ:IKT

Inhibikase Therapeutics Stock Forecast

etoro logo Buy IKT
*Your capital is at risk
$1.68
+0.0100 (+0.599%)
At Close: Jun 17, 2026
AI Analysis AI Analysis of IKT AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add IKT to Watchlist?
Some Reasons Why To Add IKT:
  • Low bankruptcy risk (Altman Z-Score: 22.00)
  • Highly efficient cash conversion (101% FCF/OCF ratio)
  • RSI at 30 — potential oversold entry point
PDF

Inhibikase Therapeutics, Inc. stock upgraded to Hold/Accumulate
(Updated on Jun 17, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Hold candidate since Jun 17, 2026

The Inhibikase Therapeutics, Inc. stock price gained 0.599% on the last trading day (Wednesday, 17th Jun 2026), rising from $1.67 to $1.68. During the last trading day the stock fluctuated 4.22% from a day low at $1.66 to a day high of $1.73. The price has fallen in 4 of the last 10 days but is still up by 0.6% over the past 2 weeks. Volume fell on the last day by -25 thousand shares and in total, 667 thousand shares were bought and sold for approximately $1.12 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -2.71% during the next 3 months and, with a 90% probability hold a price between $1.49 and $1.98 at the end of this 3-month period.

IKT Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, June 08, 2026, and so far it has risen 3.70%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Inhibikase Therapeutics, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $1.77. On a fall, the stock will find some support from the short-term average at $1.67. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Support, Risk & Stop-loss for Inhibikase Therapeutics, Inc. stock

Inhibikase Therapeutics, Inc. finds support from accumulated volume at $1.67 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0700 between high and low, or 4.22%. For the last week the stock has had daily average volatility of 3.60%.

Our recommended stop-loss: $1.60 (-4.94%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 7 days ago.)

Trading Expectations (IKT) For The Upcoming Trading Day Of Thursday 18th

For the upcoming trading day on Thursday, 18th we expect Inhibikase Therapeutics, Inc. to open at $1.69, and during the day (based on 14 day Average True Range), to move between $1.64 and $1.72, which gives a possible trading interval of +/-$0.0810 (+/-4.94%) up or down from last closing price. If Inhibikase Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 4.94% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.67 (0.60%) than the resistance at $1.70 (1.19%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Inhibikase Therapeutics, Inc. stock A Buy?

Inhibikase Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold candidate.

Current score: 0.034 Hold/Accumulate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on June 18, 2026 - $1.69 ( 0.595%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

IKT Performance

Trading levels for IKT

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 1.76 4.76%
R2 1.73 3.17%
R1 1.72 2.19%
Price 1.68
S1 1.66 -1.00%
S2 1.65 -1.98%
S3 1.62 -3.57%

Accumulated Volume Support & Resistance Levels

Level Price
R3 1.83 8.93%
R2 1.80 7.14%
R1 1.70 1.19%
Price 1.68
S1 1.67 -0.595%
S2 1.63 -2.98%
S3 1.60 -4.76%

FAQ

What is the symbol for Inhibikase Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Inhibikase Therapeutics, Inc. is IKT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Inhibikase Therapeutics, Inc. Stock?
Inhibikase Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold candidate.

How to buy Inhibikase Therapeutics, Inc. Stock?
Inhibikase Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Inhibikase Therapeutics, Inc. Stock.

What's the current price of Inhibikase Therapeutics, Inc. Stock?
As of the end of day on the Jun 17, 2026, the price of an Inhibikase Therapeutics, Inc. (IKT) share was $1.68.

What is the 52-week high and low for Inhibikase Therapeutics, Inc. Stock?
The 52-week high for Inhibikase Therapeutics, Inc. Stock is $2.26 and the 52-week low is $1.33.

What is the market capitalization of Inhibikase Therapeutics, Inc. Stock?
As of the Jun 17, 2026, the market capitalization of Inhibikase Therapeutics, Inc. is 221.815M.

When is the next earnings date for Inhibikase Therapeutics, Inc.?
The upcoming earnings date for Inhibikase Therapeutics, Inc. is Aug 13, 2026.
Click to get the best stock tips daily for free!
ABOUT INHIBIKASE THERAPEUTICS, INC.
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
7.87% Jun 12
DHI
$146.71
3.93% Jun 10
PHM
$118.49
2.86% Jun 10
EAT
$140.46
13.06% Jun 05
TPR
$140.47
3.84% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE